New hope for pancreatic cancer: targeted drug shows promise in early trial

NCT ID NCT03601923

Completed Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called niraparib in 32 people with advanced pancreatic cancer that has certain gene changes (like BRCA). The goal was to see if the drug could slow down or stop the cancer from growing. While not a cure, it offers a targeted treatment option for patients with these specific genetic features.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.